08 April 2024
08 April 2024
If given the green light, Ionis Pharmaceuticals’ olezarsen could be the first FDA-approved drug for familial chylomicronemia syndrome (FCS).
KarXT had a favourable impact on weight and metabolic parameters in the trial.
A 10% decline in risk on the primary composite endpoint for Jardiance treatment versus placebo was reported in the trial.
Despite a failed bid to expand Imfinzi’s treatment scope in NSCLC, the drug has proved effective in treating small cell lung cancer.
Keytruda biosimilar development ramps up ahead of likely patent expiry in 2028.
Reactions at the injection site were reported to be the most common adverse events observed in the trial.
Findings after an 11-month median follow-up showed that linvoseltamab treatment offered a 71% objective response rate.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
